HIV-1 protease inhibitor drug resistance in Kenyan antiretroviral treatment-naive and -experienced injection drug users and non-drug users

Table 1 Baseline characteristics of the study participants

Characteristic	Non-drug users		Injection drug users		P
Characteristic	ART (−), n = 21	ART (+), n = 32	ART (−), n = 32	ART (+), n = 47	P
Female, n (%)	16 (76.2)	20 (62.5)	18 (56.3)	30 (63.8)	0.531
Age, years	36.0 (13.8)	35.2 (10.6)	30.1 (7.2)^a	31.6 (7.4)	0.009
Duration (years) on ART, n (%)
<1	0 (0.0)	3 (9.3)	0 (0.0)	20 (42.5)
1–3	0 (0.0)	7 (21.9)	0 (0.0)	24 (51.1)	–
>3	0 (0.0)	22 (68.8)	0 (0.0)	3 (6.4)
CD4+ T cell counts/ml	568 (673)	412 (554)	532 (472)	426 (423)	0.379
Log₁₀ HIV-1 RNA, copies/ml	4.5 (2.8)	4.3 (1.6)	3.4 (2.7)^a	3.5 (2.7)^b	0.004

Data are presented as medians (IQR, interquartile range) or indicated as number (n) and proportion (%) of subjects
ART (−) anti-retroviral treatment-naive, ART (+) antiretroviral treatment-experienced, HIV-1 human immunodeficiency virus-1
^a P < 0.05 vs. ART (−) non-drug users
^b P < 0.01 vs. ART (−) non-drug users
Significant P values are shown in italic

ISSN: 1742-6405